Treatment of Global Hypokinesis
Understanding Global Hypokinesis
- Global hypokinesis is characterized by reduced left ventricular ejection fraction (LVEF), often classified as moderately depressed (30-50%) or severely depressed (<30%) 1
- Generalized decreased contractility of the myocardium is a key feature of global hypokinesis 1
- Potential development of heart failure symptoms is a concern in global hypokinesis 2
Underlying Causes
- Cardiomyopathies (dilated, hypertrophic, restrictive) are a common cause of global hypokinesis 2
- Stress-induced cardiomyopathy (Takotsubo) is another cause of global hypokinesis 3, 4
- Toxins and medications (e.g., cardiotoxic chemotherapy) can also cause global hypokinesis 2
Treatment Approach Based on Etiology
- The American College of Cardiology recommends optimal medical therapy including antiplatelet agents, statins, beta-blockers, and ACE inhibitors for global hypokinesis due to coronary artery disease 3
- For stress-induced cardiomyopathy, conventional therapy with ACE inhibitors, beta blockers, aspirin, and diuretics is recommended if hemodynamically stable 3, 4
- For heart failure with reduced ejection fraction, the American Heart Association recommends ACE inhibitors/ARBs or preferably ARNI (angiotensin receptor-neprilysin inhibitor) 2, 5
- Beta blockers (carvedilol, metoprolol succinate, or bisoprolol) are also recommended for heart failure with reduced ejection fraction 2, 5
- Mineralocorticoid receptor antagonists (spironolactone or eplerenone) are recommended for heart failure with reduced ejection fraction 2, 5
- SGLT2 inhibitors are recommended for heart failure with reduced ejection fraction 5
- Diuretics are recommended for symptom relief in fluid overload 2, 5
Device Therapy Considerations
- Cardiac resynchronization therapy (CRT) should be considered in patients who require ventricular pacing or have left bundle branch block 5
- Implantable cardioverter-defibrillator (ICD) is recommended for primary prevention in patients with persistent LVEF ≤35% despite optimal medical therapy 2
Monitoring and Follow-up
- Serial echocardiography is recommended to assess improvement in ventricular function 1
- Adjustment of medications based on clinical response and side effects is recommended 2
- Monitoring for development of complications such as thrombus formation is recommended 3, 4
Special Considerations
- Avoid long-term use of positive inotropic drugs except as palliation for end-stage disease 2
- Nutritional supplements are not recommended for treatment of heart failure with reduced ejection fraction 2